Traduction de «from smoking » (Néerlandais → Français) :

In de “ Code of Practice for the Reduction of Contamination of Food with Polycyclic Aromatic Hydrocarbons (PAH) from Smoking and Direct Drying Processes ” (in het Engels, Codex Alimentarius, CAC/RCP 68-2009) kunt u preventie- en reductiestrategieën voor PAK’s terugvinden.
Vous trouverez des stratégies de prévention et de réduction dans le “Code d’usages pour la réduction de la contamination des aliments par les hydrocarbures aromatiques polycycliques (HAP) issus des processus de fumage et de séchage direct " ( Codex Alimentarius, CAC/RCP 68-2009).

QAB149 (indacaterol) was submitted for US and EU approvals in December 2008 as a 24-hour bronchodilator for chronic obstructive pulmonary disease (COPD), an incurable condition in which the lungs have been damaged, usually from smoking.
QAB149 (indacatérol) a fait l’objet du dépôt d’une demande d’enregistrement aux Etats- Unis et en Europe en tant que broncho-dilatateur efficace durant 24 heures contre la broncho-pneumopathie chronique obstructive (BPCO), une maladie incurable qui conduit à une altération des poumons, causée habituellement par la fumée.

Protect people from tobacco smoke (bescherm iedereen tegen sigarettenrook)
Protect people from tobacco smoke (protéger tout le monde contre la fumée de la cigarette)

20. Coleman T,.Wilson A. Anti-smoking advice from general practitioners: is a population-based approach to advice-giving feasible?
20. Coleman T, Wilson A. Anti-smoking advice from general practitioners: is a population-based approach to advice-giving feasible?

Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR bupropion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.
Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR Buproprion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.